CN107223055A - 具有增强的促凋亡特性的基因修饰的传染性麻疹病毒(mv-deltac病毒)在癌症治疗中的用途 - Google Patents

具有增强的促凋亡特性的基因修饰的传染性麻疹病毒(mv-deltac病毒)在癌症治疗中的用途 Download PDF

Info

Publication number
CN107223055A
CN107223055A CN201480017539.6A CN201480017539A CN107223055A CN 107223055 A CN107223055 A CN 107223055A CN 201480017539 A CN201480017539 A CN 201480017539A CN 107223055 A CN107223055 A CN 107223055A
Authority
CN
China
Prior art keywords
deltac
pdc
cells
measles virus
cancer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201480017539.6A
Other languages
English (en)
Chinese (zh)
Inventor
F·坦吉
M·格雷瓜尔
J-F·丰特诺
J-B·吉耶尔姆
C·孔布勒代
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Centre National de la Recherche Scientifique
Institut National de la Santé et de la Recherche Médicale
Institut Pasteur
Nantes Université
Original Assignee
Centre National de la Recherche Scientifique
Universite de Nantes
Institut National de la Santé et de la Recherche Médicale
Institut Pasteur
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Centre National de la Recherche Scientifique, Universite de Nantes, Institut National de la Santé et de la Recherche Médicale, Institut Pasteur filed Critical Centre National de la Recherche Scientifique
Publication of CN107223055A publication Critical patent/CN107223055A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/15—Cells of the myeloid line, e.g. granulocytes, basophils, eosinophils, neutrophils, leucocytes, monocytes, macrophages or mast cells; Myeloid precursor cells; Antigen-presenting cells, e.g. dendritic cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/76—Viruses; Subviral particles; Bacteriophages
    • A61K35/768—Oncolytic viruses not provided for in groups A61K35/761 - A61K35/766
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/155—Paramyxoviridae, e.g. parainfluenza virus
    • A61K39/165—Mumps or measles virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5154—Antigen presenting cells [APCs], e.g. dendritic cells or macrophages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5254—Virus avirulent or attenuated
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18411—Morbillivirus, e.g. Measles virus, canine distemper
    • C12N2760/18421—Viruses as such, e.g. new isolates, mutants or their genomic sequences
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18411—Morbillivirus, e.g. Measles virus, canine distemper
    • C12N2760/18432—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18411—Morbillivirus, e.g. Measles virus, canine distemper
    • C12N2760/18434—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18411—Morbillivirus, e.g. Measles virus, canine distemper
    • C12N2760/18461—Methods of inactivation or attenuation
    • C12N2760/18462—Methods of inactivation or attenuation by genetic engineering

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Zoology (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Mycology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Cell Biology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Pulmonology (AREA)
  • Communicable Diseases (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
CN201480017539.6A 2013-01-24 2014-01-20 具有增强的促凋亡特性的基因修饰的传染性麻疹病毒(mv-deltac病毒)在癌症治疗中的用途 Pending CN107223055A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP13305086.4A EP2759301A1 (en) 2013-01-24 2013-01-24 Use of a genetically modified infectious measles virus with enhanced pro-apoptotic properties (MV-DeltaC virus)
EP13305086.4 2013-01-24
PCT/EP2014/051063 WO2014114605A1 (en) 2013-01-24 2014-01-20 Use of a genetically modified infectious measles virus with enhanced pro-apoptotic properties (mv-deltac virus) in cancer therapy

Publications (1)

Publication Number Publication Date
CN107223055A true CN107223055A (zh) 2017-09-29

Family

ID=47683672

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201480017539.6A Pending CN107223055A (zh) 2013-01-24 2014-01-20 具有增强的促凋亡特性的基因修饰的传染性麻疹病毒(mv-deltac病毒)在癌症治疗中的用途

Country Status (11)

Country Link
US (3) US9889193B2 (cg-RX-API-DMAC7.html)
EP (2) EP2759301A1 (cg-RX-API-DMAC7.html)
JP (1) JP6382223B2 (cg-RX-API-DMAC7.html)
CN (1) CN107223055A (cg-RX-API-DMAC7.html)
BR (1) BR112015017692B1 (cg-RX-API-DMAC7.html)
CA (1) CA2898370C (cg-RX-API-DMAC7.html)
DK (1) DK2948157T3 (cg-RX-API-DMAC7.html)
ES (1) ES2700749T3 (cg-RX-API-DMAC7.html)
PL (1) PL2948157T3 (cg-RX-API-DMAC7.html)
RU (1) RU2700083C2 (cg-RX-API-DMAC7.html)
WO (1) WO2014114605A1 (cg-RX-API-DMAC7.html)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN117323421A (zh) * 2022-06-24 2024-01-02 中国医学科学院医学生物学研究所 一种流感病毒介导的抗肿瘤疫苗及其制备方法和应用

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2759301A1 (en) * 2013-01-24 2014-07-30 Institut Pasteur Use of a genetically modified infectious measles virus with enhanced pro-apoptotic properties (MV-DeltaC virus)
CN107085095A (zh) * 2017-03-02 2017-08-22 江苏华冠生物技术股份有限公司 用作酶联试剂盒包被抗原的麻疹病毒裂解液的制备方法
US11633441B2 (en) 2017-12-01 2023-04-25 Gerd Sutter Immuno-modulated replication-efficient vaccinia virus strain

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101868249A (zh) * 2007-10-10 2010-10-20 巴斯德研究所 治疗间皮瘤的药物和方法
WO2012022495A1 (en) * 2010-08-20 2012-02-23 Lauer Ulrich M Oncolytic measles virus

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7118740B1 (en) 2000-09-22 2006-10-10 Mayo Foundation For Medical Education And Research Method for limiting the growth of cancer cells using an attenuated measles virus
EP1375512B1 (en) 2002-06-20 2009-07-22 Institut Pasteur Infectious cDNA of an approved vaccine strain of measles virus. Use for immunogenic compositions
CA2432738A1 (en) 2003-02-26 2004-08-26 Philippe Despres New dengue and west nile viruses proteins and genes coding the foregoing, and their use in vaccinal, therapeutic and diagnostic applications
CA2508266A1 (fr) 2005-06-20 2006-12-20 Institut Pasteur Polypeptides chimeriques et leurs applications therapeutiques contre une infection a flaviviridae
DK1939214T3 (da) 2006-12-22 2013-10-14 Pasteur Institut Celler og metodik til at generere ikke-segmenterede negativstrengede RNA-vira
US9399062B2 (en) * 2011-01-18 2016-07-26 Christopher D. Richardson PVRL4 (Nectin4) is a receptor for measles virus
EP2759301A1 (en) * 2013-01-24 2014-07-30 Institut Pasteur Use of a genetically modified infectious measles virus with enhanced pro-apoptotic properties (MV-DeltaC virus)

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101868249A (zh) * 2007-10-10 2010-10-20 巴斯德研究所 治疗间皮瘤的药物和方法
WO2012022495A1 (en) * 2010-08-20 2012-02-23 Lauer Ulrich M Oncolytic measles virus

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
ALEXANDRA VALSAMAKIS等: "Recombinant Measles Viruses with Mutations in the C, V, or F Gene Have Altered Growth Phenotypes In Vivo", 《JOURNAL OF VIROLOGY》 *
ANN M. TOTH等: "Protein Kinase PKR Mediates the Apoptosis Induction and Growth Restriction Phenotypes of C Protein-Deficient Measles Virus", 《JOURNAL OF VIROLOGY》 *
JEAN-BAPTISTE GUILLERME等: "Measles Virus Vaccine–Infected Tumor Cells Induce Tumor Antigen Cross-Presentation by Human Plasmacytoid Dendritic Cells", 《AMERICAN ASSOCIATION FOR CANCER RESEARCH》 *
JURJEN TEL等: "Natural Human Plasmacytoid Dendritic Cells Induce Antigen-Specific T-Cell Responses in Melanoma Patients", 《CANCER RESEARCH》 *
PATRICIA DEVAUX等: "Attenuation of V- or C-Defective Measles Viruses: Infection Control by the Inflammatory and Interferon Responses of Rhesus Monkeys", 《JOURNAL OF VIROLOGY》 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN117323421A (zh) * 2022-06-24 2024-01-02 中国医学科学院医学生物学研究所 一种流感病毒介导的抗肿瘤疫苗及其制备方法和应用

Also Published As

Publication number Publication date
JP2016506722A (ja) 2016-03-07
US9889193B2 (en) 2018-02-13
US10980873B2 (en) 2021-04-20
BR112015017692A2 (pt) 2019-11-19
ES2700749T3 (es) 2019-02-19
WO2014114605A1 (en) 2014-07-31
JP6382223B2 (ja) 2018-08-29
RU2015128913A (ru) 2017-03-02
DK2948157T3 (en) 2019-01-07
US10314905B2 (en) 2019-06-11
US20180221469A1 (en) 2018-08-09
US20200016260A1 (en) 2020-01-16
PL2948157T3 (pl) 2019-03-29
US20150359873A1 (en) 2015-12-17
EP2948157A1 (en) 2015-12-02
EP2948157B1 (en) 2018-10-10
EP2759301A1 (en) 2014-07-30
CA2898370C (en) 2020-01-14
BR112015017692B1 (pt) 2021-11-03
CA2898370A1 (en) 2014-07-31
RU2700083C2 (ru) 2019-09-12

Similar Documents

Publication Publication Date Title
Gauvrit et al. Measles virus induces oncolysis of mesothelioma cells and allows dendritic cells to cross-prime tumor-specific CD8 response
CA2906592C (en) Immunoprotective primary mesenchymal stem cells and methods
US10980873B2 (en) Use of a genetically modified infectious measles virus with enhanced pro-apoptotic properties (MV-deltaC virus) in cancer therapy
JP2023081859A (ja) コロナウイルスワクチン
WO2016073595A1 (en) T cells and dendritic cells for polyomavirus therapy
US20110268764A1 (en) Immune response inducing preparations
US9636395B2 (en) Medicaments and methods for treating mesothelioma
CN116650633A (zh) 冠状病毒疫苗
AU2013262426A1 (en) Cellular vaccine and method of inducing an immune response in a subject
EP2813574B1 (en) Semi-live respiratory syncytial virus vaccine
JP2022504624A (ja) 拡大された抗原性スペクトルを有するエプスタイン・バーウイルス様粒子
JP2013048597A (ja) 新型インフルエンザウイルス由来ヘマグルチニンタンパク質遺伝子を有するDIs株由来組換えワクシニアウイルス
Han et al. Development of oral CTL vaccine using a CTP-integrated Sabin 1 poliovirus-based vector system
US20250195634A1 (en) Novel usage of oncolytic gene-modified measles virus
HK40097472A (en) Coronavirus vaccine
Wu Memory CD8 T Cell Reactivation During Secondary Influenza Virus Infection

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination